21-Gene Recurrence Score Testing in HER2-positive Patients

Research output: Contribution to journalArticle

Abstract

Introduction: The 21-gene recurrence score (RS) has been extensively studied and validated in patients with estrogen receptor-positive (ER + ), human epidermal growth factor 2 (HER2)-negative breast cancer; however, RS testing is not routinely performed in patients with HER2-positive (HER2 + ) disease. We sought to determine patterns of RS testing, to characterize RS distributions, and to determine the impact of RS results on clinical decision-making for patients with ER + , HER2 + breast cancer. Materials and Methods: Using the Surveillance and Epidemiology End Results program database, we identified women with ER + , HER2 + breast cancer. We stratified patients using TAILORx RS cutoffs and evaluated treatment characteristics across patients. Multivariable logistic regression was performed to determine factors associated with RS testing and receipt of a high-risk RS. Results: Overall, 5% of patients with ER + , HER2 + , early stage breast cancer underwent RS testing. The distribution of RS testing by TAILORx cutoffs were: high-risk, 17%; intermediate-risk, 49%; and low-risk, 34%. Chemotherapy utilization among those not tested was 66%. Among those tested, utilization was significantly associated with RS results: 67% of high-risk, 30% of intermediate-risk, and 19% of low-risk patients received chemotherapy. Progesterone receptor-negative status, larger tumor size, and high tumor grade were significantly associated with high-risk RS. Conclusions: RS testing is used sparingly among patients with HER2 + early-stage breast cancer; however, test results appear to impact clinician's decision-making on chemotherapy use.

Original languageEnglish (US)
Pages (from-to)126-130
Number of pages5
JournalClinical Breast Cancer
Volume19
Issue number2
DOIs
StatePublished - Apr 1 2019

Fingerprint

Epidermal Growth Factor
Recurrence
Genes
Breast Neoplasms
Drug Therapy
SEER Program
Progesterone Receptors
Estrogen Receptors
Neoplasms
Decision Making
Logistic Models
Databases

Keywords

  • Breast cancer
  • HER2-positive
  • Recurrence score testing

PubMed: MeSH publication types

  • Journal Article

Cite this

21-Gene Recurrence Score Testing in HER2-positive Patients. / Altman, Ariella M.; Marmor, Schelomo; Tuttle, Todd M; Hui, Jane.

In: Clinical Breast Cancer, Vol. 19, No. 2, 01.04.2019, p. 126-130.

Research output: Contribution to journalArticle

@article{e5045ab50c82486d9f7e9237815a2d6c,
title = "21-Gene Recurrence Score Testing in HER2-positive Patients",
abstract = "Introduction: The 21-gene recurrence score (RS) has been extensively studied and validated in patients with estrogen receptor-positive (ER + ), human epidermal growth factor 2 (HER2)-negative breast cancer; however, RS testing is not routinely performed in patients with HER2-positive (HER2 + ) disease. We sought to determine patterns of RS testing, to characterize RS distributions, and to determine the impact of RS results on clinical decision-making for patients with ER + , HER2 + breast cancer. Materials and Methods: Using the Surveillance and Epidemiology End Results program database, we identified women with ER + , HER2 + breast cancer. We stratified patients using TAILORx RS cutoffs and evaluated treatment characteristics across patients. Multivariable logistic regression was performed to determine factors associated with RS testing and receipt of a high-risk RS. Results: Overall, 5{\%} of patients with ER + , HER2 + , early stage breast cancer underwent RS testing. The distribution of RS testing by TAILORx cutoffs were: high-risk, 17{\%}; intermediate-risk, 49{\%}; and low-risk, 34{\%}. Chemotherapy utilization among those not tested was 66{\%}. Among those tested, utilization was significantly associated with RS results: 67{\%} of high-risk, 30{\%} of intermediate-risk, and 19{\%} of low-risk patients received chemotherapy. Progesterone receptor-negative status, larger tumor size, and high tumor grade were significantly associated with high-risk RS. Conclusions: RS testing is used sparingly among patients with HER2 + early-stage breast cancer; however, test results appear to impact clinician's decision-making on chemotherapy use.",
keywords = "Breast cancer, HER2-positive, Recurrence score testing",
author = "Altman, {Ariella M.} and Schelomo Marmor and Tuttle, {Todd M} and Jane Hui",
year = "2019",
month = "4",
day = "1",
doi = "10.1016/j.clbc.2018.11.011",
language = "English (US)",
volume = "19",
pages = "126--130",
journal = "Clinical Breast Cancer",
issn = "1526-8209",
publisher = "Elsevier",
number = "2",

}

TY - JOUR

T1 - 21-Gene Recurrence Score Testing in HER2-positive Patients

AU - Altman, Ariella M.

AU - Marmor, Schelomo

AU - Tuttle, Todd M

AU - Hui, Jane

PY - 2019/4/1

Y1 - 2019/4/1

N2 - Introduction: The 21-gene recurrence score (RS) has been extensively studied and validated in patients with estrogen receptor-positive (ER + ), human epidermal growth factor 2 (HER2)-negative breast cancer; however, RS testing is not routinely performed in patients with HER2-positive (HER2 + ) disease. We sought to determine patterns of RS testing, to characterize RS distributions, and to determine the impact of RS results on clinical decision-making for patients with ER + , HER2 + breast cancer. Materials and Methods: Using the Surveillance and Epidemiology End Results program database, we identified women with ER + , HER2 + breast cancer. We stratified patients using TAILORx RS cutoffs and evaluated treatment characteristics across patients. Multivariable logistic regression was performed to determine factors associated with RS testing and receipt of a high-risk RS. Results: Overall, 5% of patients with ER + , HER2 + , early stage breast cancer underwent RS testing. The distribution of RS testing by TAILORx cutoffs were: high-risk, 17%; intermediate-risk, 49%; and low-risk, 34%. Chemotherapy utilization among those not tested was 66%. Among those tested, utilization was significantly associated with RS results: 67% of high-risk, 30% of intermediate-risk, and 19% of low-risk patients received chemotherapy. Progesterone receptor-negative status, larger tumor size, and high tumor grade were significantly associated with high-risk RS. Conclusions: RS testing is used sparingly among patients with HER2 + early-stage breast cancer; however, test results appear to impact clinician's decision-making on chemotherapy use.

AB - Introduction: The 21-gene recurrence score (RS) has been extensively studied and validated in patients with estrogen receptor-positive (ER + ), human epidermal growth factor 2 (HER2)-negative breast cancer; however, RS testing is not routinely performed in patients with HER2-positive (HER2 + ) disease. We sought to determine patterns of RS testing, to characterize RS distributions, and to determine the impact of RS results on clinical decision-making for patients with ER + , HER2 + breast cancer. Materials and Methods: Using the Surveillance and Epidemiology End Results program database, we identified women with ER + , HER2 + breast cancer. We stratified patients using TAILORx RS cutoffs and evaluated treatment characteristics across patients. Multivariable logistic regression was performed to determine factors associated with RS testing and receipt of a high-risk RS. Results: Overall, 5% of patients with ER + , HER2 + , early stage breast cancer underwent RS testing. The distribution of RS testing by TAILORx cutoffs were: high-risk, 17%; intermediate-risk, 49%; and low-risk, 34%. Chemotherapy utilization among those not tested was 66%. Among those tested, utilization was significantly associated with RS results: 67% of high-risk, 30% of intermediate-risk, and 19% of low-risk patients received chemotherapy. Progesterone receptor-negative status, larger tumor size, and high tumor grade were significantly associated with high-risk RS. Conclusions: RS testing is used sparingly among patients with HER2 + early-stage breast cancer; however, test results appear to impact clinician's decision-making on chemotherapy use.

KW - Breast cancer

KW - HER2-positive

KW - Recurrence score testing

UR - http://www.scopus.com/inward/record.url?scp=85059091924&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85059091924&partnerID=8YFLogxK

U2 - 10.1016/j.clbc.2018.11.011

DO - 10.1016/j.clbc.2018.11.011

M3 - Article

VL - 19

SP - 126

EP - 130

JO - Clinical Breast Cancer

JF - Clinical Breast Cancer

SN - 1526-8209

IS - 2

ER -